Evalstotug is a monoclonal antibody commercialized by BioAtla, with a leading Phase II program in Gastroesophageal (GE) Junction Carcinomas. According to Globaldata, it is involved in 2 clinical trials, of which 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of Evalstotug’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The revenue for Evalstotug is expected to reach an annual total of $96 mn by 2039 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Evalstotug Overview

Evalstotug (BA-3071) is under development for non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, bladder, gastric, uveal melanoma, gastroesophageal (GE) junction carcinomas, cervical, transitional cell carcinoma (urothelial cell carcinoma) and melanoma. It acts as checkpoint inhibitor by targeting against cytotoxic T-lymphocyte antigen 4 (CTLA-4). It is based on conditionally active biologics (CAB) that optimizes antibodies to be activated and/or inactivated at defined physiological conditions. It was under development for the treatment of colon adenocarcinoma.

See Also:

BioAtla Overview

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

BioAtla is a biotech company that develops novel monoclonal antibody and cell-based therapeutics using proprietary Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO) platforms. The company’s pipeline products candidate includes BA3011 (mecbotamab vedotin) targets undifferentiated pleomorphic sarcoma, non-small cell lung cancer; BA3021 (ozuriftamab vedotin) for melanoma, squamous cell carcinoma of the head and neck; BA3182 treat adenocarcinomas; BA3361 for multiple tumor types; and BA3071 (Evalstotug) treat melanoma, non-small cell lung cancer (NSCLC) and carcinomas. BioAtla is headquartered in San Diego, California, the US.
The operating loss of the company was US$129.7 million in FY2023, compared to an operating loss of US$108.1 million in FY2022. The net loss of the company was US$123.5 million in FY2023, compared to a net loss of US$106.5 million in FY2022.

For a complete picture of Evalstotug’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.